NEW YORK (GenomeWeb News) - Ipsogen said today it has inked a pact with DNAVision that allows DNAVision to offer tests based on Ipsogen’s breast cancer gene profiles in a CLIA environment.
 
Ipsogen has a portfolio of diagnostics for blood cancers that are registered in Europe as IVDs. The company said that the agreement with DNAVision enables it to launch “a new generation of IVD profiling diagnostic products addressing unmet needs in guiding breast cancer therapies.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.